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Phagocytosis is a key mechanism of innate immunity, and promotion of phagosome maturation may 
represent a therapeutic target to enhance antibacterial host response. Phagosome maturation is 
favored by the timely and coordinated intervention of lipids and may be altered in infections. Here 
we used apoptotic body-like liposomes (ABL) to selectively deliver bioactive lipids to innate cells, and 
then tested their function in models of pathogen-inhibited and host-impaired phagosome maturation. 
Stimulation of macrophages with ABLs carrying phosphatidic acid (PA), phosphatidylinositol 
3-phosphate (PI3P) or PI5P increased intracellular killing of BCG, by inducing phagosome acidification 
and ROS generation. Moreover, ABLs carrying PA or PI5P enhanced ROS-mediated intracellular killing 
of Pseudomonas aeruginosa, in macrophages expressing a pharmacologically-inhibited or a naturally-
mutated cystic fibrosis transmembrane conductance regulator. Finally, we show that bronchoalveolar 
lavage cells from patients with drug-resistant pulmonary infections increased significantly their 
capacity to kill in vivo acquired bacterial pathogens when ex vivo stimulated with PA- or PI5P-loaded 
ABLs. Altogether, these results provide the proof of concept of the efficacy of bioactive lipids delivered 
by ABL to enhance phagosome maturation dependent antimicrobial response, as an additional host-
directed strategy aimed at the control of chronic, recurrent or drug-resistant infections.
Infectious diseases represent one of the main causes of morbidity and mortality worldwide, with developing coun-
tries presenting the highest rates of mortality, and developed high-income countries still struggling with provid-
ing adequate antimicrobial therapeutic options, due to the increasing emergence of antimicrobial drug-resistant 
bacterial pathogens1. In particular, the frequency and spectrum of antibiotic resistance in specific bacterial 
pathogens responsible for respiratory tract infections continues to increase worryingly, with particular concerns 
being focused on Mycobacterium tuberculosis and on Gram-positive (Streptococcus pneumoniae, Staphylococcus 
aureus) as well as Gram-negative bacteria (Klebsiella pneumoniae, Enterobacter spp, Acinetobacter baumannii, and 
Pseudomonas aeruginosa)2. Recently, a number of strategies targeting host immune response, rather than directly 
the pathogen, have opened-up novel possibilities of treatment, in particular for multidrug-resistant tuberculosis1. 
Examples of host-directed therapies under development are represented by cellular therapy using the patient’s 
own bone marrow-derived mesenchymal stromal cells, micronutrients and other immune-modulators, antimi-
crobial peptide inducers and checkpoint inhibitors, specific immune-based therapies, and therapeutic vaccines1.
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Among the effector phases of innate immune response, phagocytosis represents the most important effector 
mechanism deputed to elimination of invading bacterial pathogens. The ingestion of bacteria is an alpha-actin 
dependent process starting with the invagination of the cell membrane to generate the phagosome, an intracellu-
lar vesicle enclosing the invading pathogen3. The phagosome is subjected to a series of fission and fusion events 
with other intracellular vesicles that cause its maturation to phagolysosome, the organelle ultimately deputed to 
microbicidal action4. The phagolysosomal maturation is driven by the topologically and temporally controlled 
expression of second lipid messengers, which can recruit signal proteins on the membrane of the maturing 
phagosome through recognition of specific lipid-binding domains5. Several second lipid messengers have been 
previously reported to promote phagolysosome maturation and intracellular mycobacterial killing6–10. Bacterial 
pathogens have also been reported to interfere with host lipid metabolism as a strategy to permit their intracel-
lular survival11. For example, Salmonella enterica introduces inside host cells a phosphoinositide phosphatases, 
SigD, in order to degrade phosphatidylinositol 4,5 bisphosphate to phosphatidylinositol phosphate (PIP), thus 
interfering with phagosome maturation12. Listeria monocytogenes, through the regulation of PI3P levels, pro-
motes the fusion of early endosomal compartments with the bacterial vacuole, before lysing the phagosome and 
escaping into cytoplasm13.
Mycobacterium tuberculosis (MTB), as well as the attenuated M. bovis Bacille Calmette-Guerin (BCG), 
interfere with phagolysosome maturation14,15 by depleting the phagosome of PI3P. Several mycobacterial prod-
ucts, including lipoarabinomannan (LAM), Secretory acid phosphatase (SapM), Zinc-dependent metallopro-
tease (ZMP), 6 kDa early secreted antigenic target (ESAT-6) and Mycobacterium tuberculosis Protein Tyrosine 
Phosphatase A (MptpA), act in concert16,17 to inhibit the conversion of the Mycobacterium-containing phagosome 
into a phagolysosome, where the bacteria would finally be degraded. Interestingly, the phosphatydilinositol ana-
logue LAM inhibits the production of PI3P by Vps34 and the activation of Vps34 by calmodulin18, whereas SapM, 
and PtpA and PtpB, two phosphatases, hydrolyze PI3P to form PI19. Moreover, MTB has been reported to inhibit 
phospholipase D (PLD) activation and, in turn, production of phosphatidic acid (PA). This inhibitory activity 
was reported as strictly related to inhibition of phagosome maturation and intracellular mycobacterial survival6. 
These data suggest that a pharmacologic approach aimed at increasing the concentration of bioactive lipids on 
maturing phagosomes would counteract microbial strategies, and may ultimately increase intracellular pathogen 
killing. However, delivery of bioactive lipids within phagocytes is challenging, due to their pharmacokinetics 
characteristics. In this context, targeting macrophages for PA delivery has been described by using Janus-faced 
apoptotic body like liposomes (ABL)20. These liposomes were prepared in order to contain i) phosphatidylserine 
(PS) at the outer surface of the liposome membrane, to make them resembling apoptotic bodies, and ii) a bioac-
tive lipid, such as PA, at the inner surface. By this strategy, it has been possible to rescue PA-dependent phagolys-
osome maturation and antimicrobial response to MTB, both in vitro and in a mouse model of TB in vivo20.
In the present study, we show that ABLs can be exploited to deliver selected second lipid messengers (i.e. PA, 
PI3P, PI5P, Arachidonic acid, sphingosine 1-phosphate, lysobisphosphatidic acid) known to positively regulate 
phagosome maturation5; their efficacy, as novel host-directed therapeutic approach, has been evaluated in mod-
els of i) bacterial interference of phagolysosome biogenesis, ii) genetically impaired phagolysosome-dependent 
antimicrobial response, and iii) drug-resistant pulmonary infections.
Results
ABLs carrying selected lipid messengers induce antimicrobial response in a model of pathogen- 
mediated interference of phagolysosome maturation. In the present study, the bioactive lipids PA, 
PI3P, PI5P, lysobisphosphatidic acid (LBPA), sphingosine 1-phosphate (S1P), or arachidonic acid (AA) chosen 
because of their capability to promote phagosome maturation5, were individually included in the inner layer of 
ABLs, to test their activity as enhancer of intracellular mycobacterial killing. The ABL preparations containing 
the selected lipids were preliminarily tested in flow cytometry for size distribution by comparing their forward 
scatter parameters (FS) with the FS of commercially available beads of known diameter. Results show a similar FS 
distribution for all ABLs tested (Supplementary Fig. 1d–i), which almost overlapped with the distribution of 1 μ m 
beads (Supplementary Fig. 1c). Then, we analyzed the impact of the different ABLs on phagosome acidification 
of differentiated THP-1 (dTHP1) cells, infected or not with BCG. Results indicate that stimulation of dTHP1 
with PA-, PI3P- or PI5P-loaded ABLs increases phagosome acidification to a pH of 5–5.5 in both uninfected 
(Fig. 1a) and BCG-infected (Fig. 1b) cells. This result was confirmed using NHS-labeled BCG. NHS is a pH 
sensitive fluorochrome whose fluorescence decreases proportionally to acidification of the microenvironment 
(Supplementary Fig. 2). Results show that when NHS–labeled BCG infected dTHP1 cells are treated with 
PA-, PI3P- or PI5P-loaded ABL, the mean fluorescence of BCG was reduced in comparison with untreated 
dTHP1 cells or with dTHP1 cells treated with other ABLs (Fig. 1c). As autophagy has been reported to be part 
of the innate antimicrobial armamentarium21, we assessed autophagy flux (the autophagy on-rate/off-rate) by 
monitoring LC3II cellular levels in the presence or absence of the lysosome inhibitor NH4Cl to allow LC3II 
accumulation22. Results show that intravacuolar acidification was associated with the enhancement of LC3II lev-
els (Supplementary Fig. 3a,b), which occurs earlier (at 3 hours post-infection) in BCG-infected cells after stimu-
lation with PI3P-loaded ABL, and later (at 18 hours post-infection) in uninfected cells after stimulation with PA-, 
PI3P- or PI5P-loaded ABL.
Phagosome maturation and ROS generation are sequential steps leading to intracellular bacterial killing23. As 
type II NADPH oxidase (NOX-2) assemblies from component subunits on maturing phagosomes24, we moni-
tored ROS generation following stimulation with the ABLs inducing phagosome maturation in both uninfected 
and BCG infected macrophages. In this context, PA-, PI3P- or PI5P-loaded ABLs were able to induce ROS gen-
eration in uninfected (Fig. 2a–c) and BCG infected macrophages (Fig. 2d–f), with a peak at 20 minutes (Fig. 2a) 
and 18 hours (Fig. 2f) after stimulation, respectively, suggesting the initial interference exerted by BCG with 
phagosome maturation and hence with NOX-2 assembly.
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To measure the functional consequences of phagosome maturation and ROS generation, we measured 
BCG viability following stimulation with the same ABLs. In agreement with the above reported results, PA-, 
PI3P- or PI5P-loaded ABLs significantly enhanced intracellular mycobacterial killing, as detected by CFU assay 
(Supplementary Fig. 4a) or by BCG-lux assay in dTHP1 cells (Supplementary Fig. 4b) as well as in primary 
macrophages (Supplementary Fig. 4c). To confirm that the increased intracellular BCG killing induced by ABLs 
carrying PA, PI3P or PI5P was dependent by ROS generation, cells were exposed to pegylated catalase (PEG-Cat), 
which is known to convert hydrogen peroxide to water and oxygen, eventually reducing ROS activity. Results 
indicate that PEG-Cat almost completely abolishes the ABL-induced intracellular BCG killing (Fig. 3), highlight-
ing that the main mechanism of ABLs action relies on ROS generation. Finally, the results obtained with PA-, 
PI3P- or PI5P-loaded ABLs were not associated to cytotoxic effects: viability of treated dTHP1 cells was almost 
unchanged if measured after 1, 3 and 5 days following ABLs stimulation and was indistinguishable from that of 
untreated cells (Supplementary Fig. 5).
PA or PI5P delivered by ABLs rescue the impairment of antimicrobial immune response 
dependent upon CFTR inhibition. Cystic Fibrosis Transmembrane Regulator (CFTR) participates 
in phagolysosome biogenesis permitting intraphagosomal influx of chloride ions (Cl−) to balance the electric 
gradient that is generated by the vATPase-dependent proton accumulation in maturing phagosomes25. In the 
absence of Cl− influx, the accumulation of positive charges prevents further acidification26 and macrophages 
show diminished antimicrobial response27. In this context, we preliminarily confirmed that the pharmacolog-
ical inhibition of CFTR by exposure to INH172 affected the phagosome acidification of primary macrophages 
phagocytizing latex beads (Supplementary Fig. 6a) as well as their capability to kill the P. aeruginosa strain PAO1 
(Supplementary Fig. 6b). Given their capacity to promote phagolysosome maturation and ROS-mediated bac-
tericidal response, we tested ABLs carrying PA, PI3P or PI5P on primary macrophages from healthy subjects 
Figure 1. ABLs carrying selected bioactive lipids facilitate phagolysosome maturation. dTHP1 cells were 
uninfected (a) or infected (b) with BCG at the MOI of 5, treated with ABLs carrying the indicated bioactive 
lipid for 18 hours and then stained with Lysosensor green DND189 for pH determination. Results are shown as 
mean ± standard deviation of the values obtained from the triplicate of each condition and are representative of 
three separate experiments. *p < 0.001 in comparison with untreated control by one sided Student’s t Test.  
(c) BCG was labeled with 100 μ g/ml of the pH sensitive dye NHS and used to infect dTHP1 cells (MOI 
5). Infected cells were then treated with ABLs carrying the indicated bioactive lipid. The fluorescence 
expressed in relative fluorescence units is directly proportional to intraphagosomal pH. Results are shown as 
mean ± standard deviation of the values obtained from the triplicate of each condition and are representative of 
three separate experiments. *p < 0.001 in comparison with untreated control by one sided Student’s t test.
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with pharmacologically inhibited or genetically mutated CFTR after in vitro infection with PAO1. Results show 
that the treatment of PAO1-infected primary macrophages with PI5P-loaded ABLs increased the intracellular 
Figure 2. ABLs carrying selected bioactive lipids promote ROS production. Uninfected (a–c) or BCG 
infected (MOI 5) dTHP1 cells (d–f) were labeled with DCF at a concentration of 10 μ M and subsequently 
treated with ABLs carrying the indicated bioactive lipid for 20 (a,d), 40 minutes (b,e) or 18 hours (c,f). The 
intensity of the fluorescence of DCF is proportional to the amount of ROS produced. The results are shown as 
mean ± standard deviation of relative fluorescence units performed in triplicates and are representative of 3 
separate experiments. *p < 0.0001 in comparison with untreated control (a), or with BCG infected untreated 
control (f) by one sided Student’s t test.
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bacterial killing capacity of macrophages with functional (Fig. 4c) or pharmacologically inhibited CFTR (Fig. 4f). 
This effect was specific for PI5P-loaded ABLs, since treatment with PA-loaded ABLs was only active on mac-
rophages with pharmacologically inhibited CFTR (Fig. 4d), whereas PI3P-loaded ABLs were ineffective in this 
model (Fig. 4b,e). The mechanism of action of ABLs was confirmed to be dependent by the increased ROS pro-
duction, since the treatment with ABL/PA or ABL/PI5P was ineffective in the presence of PEG-Cat (Fig. 5).
The promising results obtained with PA- or PI5P-loaded ABLs on cells with pharmacologically inhibited CFTR 
prompted us to evaluate the consequences of ABL treatment on primary monocyte-derived macrophages isolated 
by 8 patients affected by cystic fibrosis (CF). Macrophages from CF patients were infected in vitro with PAO1, and 
bacterial killing was measured by CFU counting. Results show that ABLs carrying PA or PI5P (Fig. 6a,c) increase 
the killing capacity of macrophages with CF mutations, while the treatment with PI3P-loaded ABLs was ineffec-
tive (Fig. 6b), confirming data obtained in macrophages whose CFTR function was pharmacologically inhibited.
ABLs carrying selected bioactive lipids enhance antimicrobial response in BAL cells iso-
lated from patients with infectious pneumonia. The reported results suggest the feasibility of an 
ABL-mediated delivery of bioactive lipids into infected cells as a possible immunotherapeutic option to increase 
the innate cell-mediated clearance of pulmonary bacterial pathogens. As a preclinical model of efficacy, we there-
fore evaluated the efficacy of the ABL treatment in an ex vivo model of antibiotic resistant infections. The efficacy 
of ABLs carrying PA, PI5P or PI3P was tested in bronchoalveolar lavage (BAL) cells isolated from 6 patients 
affected by pneumonia, caused by the following different bacterial pathogens: Klebsiella pneumoniae (patient 
#1), Klebsiella oxytoca (patient #2), Pseudomonas aeruginosa (patients #3 and #6), Staphylococcus aureus (patient 
#4). Patient #5 had an Escherichia coli and Acinetobacter baumannii co-infection. Bacterial isolates had variable 
levels of antibiotic resistance (Tables 1 and 2) and A. baumannii was the most resistant, showing susceptibility to 
colistin, only (Table 1). Bacterial CFUs were measured after overnight culture of BAL cells treated or not with PA-, 
PI3P- or PI5P-loaded ABLs. Results show that a significant increase of intracellular killing of all bacterial patho-
gens was observed after treatment of BAL cells with PA- or PI5P-loaded ABLs, while treatment with PI3P-loaded 
ABLs was only effective in Escherichia coli infection (Fig. 7).
Discussion
The emergence of drug-resistant bacterial pathogens with epidemic potential is a major global concern1. In 
2015, an estimated 1.8 million people died worldwide from tuberculosis and 480000 new cases were reported 
with multi-drug resistant and extensively drug resistant tuberculosis28. Moreover, 23000 and 25000 deaths are 
attributable to antibiotic-resistant infections each year in the United States29 and in Europe30, and common eti-
ologic agents are represented by multidrug- and pan-antibiotic- resistant Gram-negative and Gram-positive 
bacteria, such as Pseudomonas spp, Acinetobacter spp, Streptococcus penumoniae, Staphylococcus aureus, and 
Enterobacteriaceae, including endogenous bacteria. In one survey of US health centres, 78% of Gram-negative 
bacteria were resistant to all antibiotics except colistin (to which 62% of Acinetobacter spp, 59% of Pseudomonas 
spp, and 52% of Enterobacter spp were resistant)31. Many patients show increased susceptibility to these infec-
tions, including those who are immunosuppressed, receiving intensive care or with chronic lung pathologies 
such as bronchiectasis, chronic obstructive pulmonary disease and cystic fibrosis32. Notably, chronic respiratory 
infections are also the main cause of morbidity and mortality in patients with CF, which is the most common fatal 
single gene disorder. One of the hallmarks of these infections, led by the opportunistic pathogen P. aeruginosa, is 
their long-term (lifelong) persistence, despite intensive antimicrobial therapy, which reflects the rapid acquisition 
of multidrug resistance33. As a consequence, a growing awareness is emerging for the development of novel anti-
bacterial agents and/or other immunotherapeutic options2.
Figure 3. ABLs promote intracellular mycobacterial killing by a ROS dependent mechanism. dTHP1 cells 
were infected with BCG at the MOI of 5 and then treated for 3 days with ABLs carrying PA, PI3P, or PI5P in the 
presence or absence of 100 U/ml PEG-Cat. Results are expressed as mean ± standard deviation of CFU values 
performed in triplicate and are representative of two independent experiments. *p < 0.01 and **p < 0.0001 by 
one sided Student’s t test.
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Figure 4. ABLs carrying PA or PI5P promote intracellular bacterial killing in primary macrophages 
expressing a pharmacologically inhibited CFTR. Monocyte derived macrophages (MDM) isolated from 
healthy subjects (n = 8) were infected with P. aeruginosa, as described in materials and methods, and then 
treated for 2 hours with the ABLs carrying PA, PI3P or PI5P in the absence (a–c) or in the presence (d–f) or of 
the CFTR inhibitor INH172. Bacterial growth was assessed by CFU assay. The results shown are obtained from 
triplicate for each condition. Statistical analysis was performed by using two sided Wilcoxon matched-pairs 
signed rank test and p value is indicated in the single panels.
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In the present study, we have generated, tested and selected apoptotic body-like liposomes carrying bioactive 
lipids involved in phagosome maturation for their capacity to enhance antimicrobial response. The efficiency 
of these ABLs to improve bactericidal response was first tested in two models of inefficient phagosome matura-
tion: the bacterial interference of phagolysosome biogenesis, i.e. the infection with BCG34,35, and the impaired 
phagolysosome dependent antimicrobial response, i.e. the model of CF27. In the model of BCG infection of 
macrophages, we showed that in addition to ABLs carrying PA, that were previously described20, also PI3P- or 
PI5P-loaded ABLs were able to significantly increase intraphagosomal acidification and to induce ROS production 
and ultimately promote intracellular mycobacterial killing in macrophages. PI3P has a well-known role in phago-
lysosome biogenesis and is critical for autophagy21,36. In fact, PI3P increase at the phagosome membrane level 
may recruit proteins associated with autophagy initiation, such as DCFP1 (double FYVE-containing protein 1) 
and WIPI (WD-repeat protein interacting with PI) proteins37. Moreover, PI3P appears to be important in the acti-
vation of NADPH oxidase in the phagosome, because it can interact with and activate the p40phox subunit of the 
enzyme38. PI5P has a not yet entirely defined mechanism of action, but it has been reported to be involved in dif-
ferent processes, such as (i) traffic regulation of intracellular vesicles and phagolysosome maturation through the 
stimulation of miotubularins39, (ii) chromatin-mediated control of gene expression40, (iii) cytoskeleton remode-
ling41 and (iv) activation of a non-canonical autophagy, which is independent of the class III phosphatidylinositol 
3-kinase (PI3K), Vps3442. The mechanism of action of PA in phagolysosome maturation is also still unclear, but 
it appears to control membrane dynamics by directly affecting the physico-chemical properties of lipid bilayers 
independently of protein effectors43. In fact, PA is a cone shaped lipid, due to the small polar head in compari-
son to its hydrocarbon tail, and it can promote the membrane curvature and the subsequent fusion and fission 
processes, so favoring phagocytosis and phagosome maturation20,44 and the activation of NADPH oxidase45. 
Interestingly, acidification of phagosomes containing BCG was associated with LC3II accumulation after stim-
ulation with PI3P-loaded ABL, only. These results support the crucial role played by PI3P in autophagy activa-
tion and in intracellular mycobacterial killing35 and suggest that, an autophagy-independent, phagolysosome 
maturation-dependent intracellular BCG killing is activated following stimulation with ABL carrying PA or PI5P.
The CF model was chosen as it is characterized by the impairment of mucosal immune response as a result of 
CFTR mutations46, whose malfunction is responsible for the block of phagolysosome maturation25 and for the 
reduced antimicrobial response27,47. We confirmed that the dysfunction of the CFTR channel caused by genetic 
mutation in CF patients or by pharmacological inhibition alters phagosomal acidification of macrophages and 
their microbicidal capability against a relevant CF related bacterial pathogen, such as P. aeruginosa. In this model, 
the use of PA- or PI5P-loaded ABLs restored the function of macrophages with pharmacologically inhibited 
CFTR or isolated by CF patients. The efficacy of PA- or PI5P-loaded ABLs has been also confirmed on BAL cells 
from patients with bacterial pneumonia, used as a clinically relevant model of drug resistant infection.
Together, these data are consistent with the key role of ROS in the intracellular killing of bacterial pathogens24. 
Although the mechanism through which PI5P may induce ROS generation is still not known and needs fur-
ther investigation, the involvement of PA in the activation of NADPH oxidase in phagocytic cells has been 
reported45,48.In these last two models, we noticed a substantial inefficacy of the treatment of macrophages 
with PI3P-loaded ABLs in terms of intracellular bacterial killing. A possible explanation of this phenome-
non is that PI3P conveyed by ABLs promotes autophagy, which contributes to protection against intracellular 
Figure 5. ABLs carrying PA or PI5P induce ROS dependent intracellular killing of P. aeruginosa. Primary 
monocyte derived macrophages (106 cells/ml) were exposed to the CFTR inhibitor INH172 at a concentration 
of 10 μ M and infected with P. aeruginosa, as described in materials and methods, and then treated for further 
2 hours with the indicated ABLs in the presence or absence of catalase (PEG-Cat), used at the concentration of 
100 U/ml. Bacterial growth was assessed by CFU assay. The results are shown as mean ± standard deviation of 
the values obtained from the triplicate of each condition and are representative of two separate experiments. 
*p < 0.0001 by one sided Student’s t test.
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Figure 6. ABL carrying PA or PI5P promote intracellular bacterial killing in CF macrophages. Monocyte 
derived macrophages (106 cells/ml), isolated from CF patients (n = 8), were infected with P. aeruginosa, as 
described in materials and methods, and then treated for further 2 hours with ABL/PA (a), ABL/PI3P (b), or ABL/
PI5P (c). Bacterial growth was assessed by CFU assay. Survival is expressed as a percentage of bacterial survival and 
was calculated as the ratio between the CFU obtained after two hours of infection in the presence or absence of the 
indicated ABLs and the CFU obtained at time 0, before the addition of the ABLs. Statistical analysis was performed 
by using two sided Wilcoxon matched-pairs signed rank test and p value is indicated in the single panels.
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mycobacteria35, such as BCG. Other bacteria, such as, P. aeruginosa have been reported to trigger autophagy to 
escape intracellular killing49, and the induction of autophagy by PI3P delivered by ABLs may be irrelevant or even 
concur to this escape50. Similarly to P. aeruginosa, a strategy of autophagy manipulation has been described for S. 
aureus and A. baumannii, which reside in immature LC3II+ autophagosomes, as a niche for their replication51,52. 
Thus, bacterial pathogens may exploit different strategies to manipulate (auto)phagosome maturation and these 
features may probably reflect the differences observed with PA-, PI5P- or PI3P-loaded ABLs.
The ABL-enhanced antimicrobial activity in BAL cells represents a preclinical model of ABL efficacy, as the 
results are obtained in a cell microenvironment mirroring that of the infected lung and, hence, may be predictive 
of the possible in vivo action of ABL if delivered by aerosolic route53. The translational value of the results reported 
herein is further emphasized by the significant intracellular killing of different bacterial species characterized by a 
wide-spectrum of antibiotic resistance, such as A. baumannii of sample #5, for example, that showed resistance to 
K. pneumoniae 
(patient #1)
K. oxytoca 
(patient #2)
P. aeruginosa 
(patient #3)
E. coli 
(patient #5)
A. baumannii 
(patient #5)
P. aeruginosa 
(patient #6)
Ampicillin ≥ 32 (R) 16 (R) ≥ 32 (R) ≥ 32 (R) ≥ 32 (R) ≤ 2 (S)
Amoxycillin/Clavulanic acid ≥ 32 (R) ≤ 2 (S) ≥ 32 (R) 16 (R) ≥ 32 (R) 4 (S)
Piperacillin/Tazobactam 64 (R) ≤ 4 (S) 8 (S) 64 (R) ≥ 128 (R) n.d.
Cefoxitin ≤ 4 (S) ≤ 4 (S) n.d. ≤ 4 (S) n.d. n.d.
Cefotaxime ≤ 1 (S) ≤ 1 (S) ≥ 64 (R) ≥ 64 (R) ≥ 64 (R) ≤ 1 (S)
Ceftazidime ≤ 1 (S) ≤ 1 (S) 4 (S) 16 (R) ≥ 64 (R) ≤ 1 (S)
Cefepime ≤ 1 (S) ≤ 1 (S) 2 (S) ≥ 64 (R) ≥ 64 (R) ≤ 1 (S)
Ertapenem ≤ 0.5 (S) ≤ 0.5 (S) ≥ 8 (R) ≤ 0.5 (S) ≥ 8 (R) ≤ 0.5 (S)
Imipenem ≤ 0.25 (S) ≤ 0.25 (S) 1 (S) ≤ 0.25 (S) ≥ 16 (R) 1 (S)
Meropenem ≤ 0.25 (S) ≤ 0.25 (S) 2 (S) ≤ 0.25 (S) n.d. ≤ 0.25 (S)
Amikacin ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) 4 (S) n.d. 4 (S)
Gentamicin ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≥ 16 (R) ≥ 16 (R) ≤ 1 (S)
Ciprofloxacin ≤ 0.25 (S) ≤ 0.25 (S) ≤ 0.25 (S) ≥ 4 (R) ≥ 4 (R) ≤ 0.25 (S)
Tigecycline 1 (S) ≤ 0.5 (S) n.d. ≤ 0.5 (S) 2 (i.e.) n.d.
Fosfomycin ≤ 16 (S) ≤ 16 (S) n.d. ≤ 16 (S) ≥ 256 (R) n.d.
Nitrofurantoin n.d. n.d. n.d. ≤ 16 (S) n.d. 128 (R)
Colistin ≤ 0.5 (S) ≤ 0.5 (S) ≤ 0.5 (S) ≤ 0.5 (S) ≤ 0.5 (S) 1 (S)
Trimethoprim/Sulfamethoxazole ≥ 320 (R) ≤ 20 (S) n.d. ≥ 320 (R) ≥ 32 (R) ≤ 20 (S)
Table 1.  Antibiogram of Gram- clinical isolates by BAL samples. (R) = resistant; (S) = sensitive; n.d. = not 
determined; i.e. = insufficient evidence that the organism or group is a good target for therapy with the agent.
S. aureus (patient #4)
Cefoxitin screening positive
Benzil penicilline ≥ 0.5 (R)
Oxacilline ≥ 4 (R)
Gentamicin ≤ 0.5 (S)
Levofloxacin ≥ 8 (R)
Clindamicin inducible resistance positive
Erithromicin ≥ 8 (R)
Clindamicin 0.25 (R)
Linezolid 2 (S)
Daptomicin 0.25 (S)
Teicoplanin ≤ 0.5 (S)
Vankomicin 1 (S)
Tetraclicin ≤ 1 (S)
Tigecycline ≤ 0.12 (S)
Fosfomycin n.d.
Fusidic Acid ≤ 0.5 (S)
Mupirocine n.d.
Rifampicin ≤ 0.03 (S)
Trimethoprim/Sulfamethoxazole ≤ 10 (S)
Table 2.  Antibiogram of S. aureus isolated by BAL sample (patient #4).
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Figure 7. The microbicidal function of BAL cells from bacterial pneumonia patients is enhanced by ABLs. 
Bronchoalveolar lavage cells, from 6 patients with bacterial pneumonia, were treated for 18 hours with the 
indicated ABLs. Intracellular bacterial growth was evaluated by CFU. The number above each column indicates 
the percentage of killing is indicated above each column and was calculated by using the following formula: 
(1- CFU sample treated with ABLs/CFU untreated control) x100. The results are shown as mean ± standard 
deviation of the values obtained from the triplicate of each condition. ○ p < 0.05, ● p < 0.001, and *p < 0.0001 in 
comparison with untreated cells by one sided Student’s t test.
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all tested antibiotics except Colistin. Considering the global emergence of antibiotic resistance and the low num-
ber of new antimicrobial agents actually in clinical development, it is urgent to identify novel strategies aimed at 
simultaneously increasing the antimicrobial arsenal and preserving the already available drugs54. Together, the 
results reported herein represent the proof of concept of the feasibility of an effective and innovative host-directed 
therapeutic approach where PA or PI5P (or other selected bioactive lipids) may be delivered to effector phagocytic 
cells by aerosolized ABLs to enhance (auto)phagolysosome mediated antibacterial response. Although next in 
vivo validation in relevant animal models will be necessary and therapeutic regimens and dosage of adminis-
tration need to be identified before of the transfer to clinical development, ABL based strategy may represent 
a promising therapeutic option which can be exploited to treat bacterial pathogens that have acquired or are 
expected to acquire antibiotic resistance.
Methods
Liposome preparation. ABLs were produced as previously described20. Briefly, the inner monolayer lipids 
(0.05 mg/ml) were suspended in anhydrous dodecane (Sigma). The following bioactive lipids were used for the 
inner monolayer: L-α -phosphatidic acid; 1,2-dioleoyl-sn-glycero-3-phospho-(1′ -myo-inositol-3′ -phosphate) 
(PI3P); 1,2-dioleoyl-sn-glycero-3-phospho-(1′ -myo-inositol-5′ -phosphate) (PI5P); D-erythro-sphingosine-
1-phosphate (S1P); Lysobisphosphatidic acid (LBPA), (All by Avanti Polar Lipids) or Arachidonic Acid (AA) 
(Sigma). L-α -phosphatidylserine (PS) (Avanti Polar Lipids) was used as outer monolayer lipid and was added 
to a 99:1 dodecane:silicone solution to obtain a final concentration of 0.05 mg/ml. Asymmetric liposomes were 
prepared by adding 2 ml of outer monolayer lipid suspension over 3 ml of complete medium. Finally, 100 μ l of the 
inner monolayer lipid suspensions were added over 2 ml lipid phase and the samples were centrifuged at 120 g 
for 10 minutes. After the centrifugation, ABLs were collected in an aqueous phase using a 5 ml syringe with a 
16-gauge stainless steel needle. The following six different ABL formulations were produced: PS outside/PA inside 
(ABL/PA), PS outside/PI3P inside (ABL/PI3P), PS outside/PI5P inside (ABL/PI5P), PS outside/S1P inside (ABL/
S1P), PS outside/LBPA inside (ABL/LBPA), and PS outside/AA inside (ABL/AA). Liposomes were then quanti-
fied by a flow cytometer FACSCalibur (Becton Dickinson), allowing quantification of monodispersed vesicles > 
0.2 μ m in diameter.
Cell culture. Human pro-monocytic THP-1 leukemia cell line was supplied by European Collection of 
Cell Culture, grown in RPMI 1640 containing fetal bovine serum (10%), gentamycin (5 μ g/ml), L-glutammine 
(2 mM), nonessential amino acids (1 mM), sodium pyruvate (1 mM) and cultured in 75 cm2 polystyrene flasks. 
Before experiments, cells (5 × 105 per well) were seeded in 24-well plates and cells were induced to differentiate by 
stimulation for 72 hours with Phorbol 12-Myristate 13-Acetate (PMA) (20 ng/ml), and used as a model of human 
macrophages.
Primary monocyte derived macrophages were prepared as previously described47. Briefly, peripheral blood 
mononuclear cells were isolated by healthy donors or Cystic Fibrosis patients and monocytes were separated, 
by using anti-CD14 monoclonal antibodies conjugated to magnetic microbeads (Miltenyi Biotec), according to 
manufacturer’s instructions. Monocytes were then suspended in complete medium and incubated for a further 
5 days in 96-well plates at the concentration of 2 × 105 cells/well in the presence of M-CSF (50 ng/mL) (R&D 
Systems) to get differentiated macrophages.
Bacteria. Mycoacterium bovis BCG Pasteur strain (TMC1011) was grown and titred as described14. BCG 
transformed with the plasmid carrying luciferase gene (BCG-lux), kindly provided by Prof. R. Reljic from S. 
George’s University of London (UK), was grown as previously described55. Pseudomonas aeruginosa (PAO1 
strain) were isolated by streaking on Pseudomonas isolation agar (PIA) (BD Difco TM), single bacterial colonies 
were collected and suspended in 15 ml of Luria-Bertani medium and grown in Erlenmeyer flask at 37 °C under 
stirring for 18 hours. The growth of bacterial cultures was monitored by measuring the optical density at the 
wavelength of 600 nm by a spectrophotometer (Ultrospec 1100pro, Amersham Biosciences). Bacilli were stored 
at − 80 °C until use after suspension in Luria-Bertani medium and 30% glycerol.
Infection and evaluation of intracellular (myco)bacterial growth. dTHP1 cells or primary mac-
rophages were distributed in triplicate in 24 well plate (5 × 105 cells per well) and exposed for 3 hours to BCG or 
to BCG-lux at the multiplicity of infection (MOI) of 5 or 10, respectively. After removal of extracellular bacilli, 
cells were treated with the indicated different ABLs added to a ratio of 1 to 1 (ABL:cell). Intracellular BCG 
growth was monitored by CFU assay14 or by luminometric assay55 performed after 3 hour exposure and at day 
3 post-infection, by plating bacilli in triplicate after lysis of cells with saponin. Mycobacterial luminescence has 
been evaluated by Varioskan LUX Multimode Microplate Reader (Thermo Fisher Scientific).
Primary macrophages were distributed in triplicate in 96 well plates (2 × 105 cells per well) and infected with 
P. aeruginosa for 1 hour at 37 °C at a MOI of 30 in the presence or absence of CFTR inhibitor (INH172, Sigma), 
used at the concentration of 10 μ M. Thereafter, extracellular bacilli were killed by 1 hour incubation with gen-
tamicin (400 μ g/ml). Cells were then washed and incubated with PA-, PI3P- or PI5P-loaded ABLs, added to 
a ratio of 1 to 1 (ABL:cell), for further 2 hours in the presence or absence of INH172. Finally, cells were lysed 
with 1% deoxycholate (Sigma), samples diluted in PBS-tween 80 and CFU quantified by plating bacilli in tripli-
cate on PIA. In order to evaluate the role of ROS in intracellular (myco)bacterial killing, BCG-infected cells or 
PAO1-infected cells were treated with PEG-Catalase (100 U/ml), as described20.
Fluorometry. Phagosome acidification was assessed by using the fluorescent probe Lysosensor green DND 
189 (Molecular Probes)56, which measures pH of acidic organelles such as phagolysosomes. Briefly, dTHP1 
cells were infected or not with BCG and then treated or not with the different ABLs for 18 hours. Cells were 
then stained for 15 minutes at 37 °C with Lysosensor green DND 189 (1 μ M). pH acidification was evaluated by 
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fluorometry by setting the wavelength of excitation at 443 nm and emission at 505 nm according to the manu-
facturer’s instructions. Intraphagosomal acidification of vacuoles containing BCG was monitored by using BCG 
labeled with pH sensitive dye N-hydroxysuccin-imidyl 5-(and 6-)-carboxyfluorescein (NHS-CF) (100 μ g/ml, 
Sigma), as described57. In particular, dTHP1 cells were infected in triplicate with NHS labeled BCG for 3 hours 
at the MOI of 5 and then treated overnight with the different ABLs. pH dependent fluorescence emission by 
NHS-labeled BCG was preliminarily confirmed by incubating BCG-NHS for 15 minutes at 37 °C in buffers cal-
ibrated at pH 4.5, 5.5, 6.5, 7.5 (from Intracellular pH Calibration Buffer Kit, Molecular Probes). The intensity of 
fluorescence was determined at an excitation wavelength of 492 nm and emission wavelength of 517 nm.
ROS generation was analyzed by loading cells with the fluorescent indicator 20,70-dichlorofluorescein diac-
etate (DCF) (Molecular Probes), used at the concentration of 10 μ M, for 60 min at 37 °C in the dark. Thereafter, 
cells were infected or not with BCG, washed twice and treated with the different ABLs for 20, 40 minutes and 
18 hours. The production of ROS was evaluated by fluorometry by setting the wavelength of excitation and emis-
sion at 488 nm and 530 nm, respectively.
Fluorescence has been evaluated by the use of a Varioskan LUX Multimode Microplate Reader (Thermo 
Fisher Scientific).
Patients. Cystic fibrosis patients (n = 8) were enrolled at “Bambino Gesù” Children’s Hospital in Rome, Italy. 
All of the CF patients were clinically stable at the time of blood donation (5 ml). Controls (n = 8) were repre-
sented by buffy coats from healthy blood donors attending at the local Blood Transfusion Unit of Policlinico “Tor 
Vergata” in Rome. Clinical and demographic features of CF patients as well as healthy controls are summarized 
in Supplementary Table 1.
Patients with bacterial pneumonia (n = 6) were enrolled at the Department of Pulmonary Medicine of 
Fondazione Policlinico Universitario A. Gemelli, Rome. Clinical and demographic features of the patients are 
summarized in Supplementary Table 2. BALs were collected, following the guidelines of “American Thoracic 
Society Committee”58, at Bronchial Endoscopy Unit of Fondazione Policlinico Universitario Gemelli in Rome.
Bacterial isolates were identified by Matrix-Assisted Laser Desorption Ionization-Time-Of-Flight mass spec-
trometry (Bruker Corporation). Minimum inhibitory concentrations (MICs) were determined with the Vitek 2 
(β -lactam inhibitor combinations, oxyimino-cephalosporins, carbapenems, aztreonam, quinolones, aminogly-
cosides), the E-test (bioMérieux, Inc) with cation-adjusted Mueller-Hinton agar (colistin), or Sensititre broth 
microdilution (Thermo Fisher Scientific) (tigecycline). Colistin MICs for Enterobacteriaceae isolates were clas-
sified using EUCAST breakpoints (susceptible, MIC ≤ 2 mg/L; resistant, MIC > 2 mg/L)59. US Food and Drug 
Administration breakpoints were used for tigecycline MICs (susceptible ≤ 2 mg/L; resistant, ≥ 8 mg/L)60. Other 
MICs were interpreted according to Clinical and Laboratory Standards Institute breakpoints (http://www.eucast.
org). Diagnostic quantitative culture thresholds were 104 cfu/mL.
All patients gave written informed consent and the clinical studies were performed in accordance with the 
relevant guidelines and regulations and were approved by the local Ethics Committee. Cystic fibrosis patients, giv-
ing their (or parental) informed consent to participate to the study, were enrolled at “Bambino Gesù” Children’s 
Hospital in Rome after having received detailed information on the scope and objectives of the study by a san-
itary personnel explained patient information leaflet (ethics approval #738/2014 of “Bambino Gesù” Children’s 
Hospital, Rome). Patients with bacterial pneumonia were enrolled at the Department of Pulmonary Medicine of 
Catholic University of Sacred Heart in Rome and were invited to participate through a patient information leaflet 
(ethics approval #20388/2013 of Catholic University of Sacred Heart, Rome).
BAL cells and stimulation with ABLs. BAL cells were treated as previously described20 and suspended as 
106 cells/mL in medium consisting of RPMI 1640 supplemented with 10% FBS, 2 mM L-Glu, 5 μ g/ml Gentamycin, 
5 μ g/mL Ampicillin, and 2 μ g/ml Fluconazole (all from Invitrogen) and incubated for 18 hours in 24-well plates 
in the presence or absence of the different ABLs used at the ratio of 1 liposome per cell. Respiratory bacterial 
specimens were quantitatively cultured on blood, chocolate, or MacConkey agars.
Statistics. Comparison between groups was done using Student’s t test, as appropriate for normally distrib-
uted data. The Wilcoxon rank sum test was performed for data that were not normally distributed. Analysis of 
western blotting data has been performed by means of ANOVA and Bonferroni post-test to estimate the differ-
ences between selected samples. p < 0.05 was considered to be statistically significant.
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